Physician profile
Colin Brown
NPI 1053371203
$4,250.63
in general payments reported to CMS, 2019-2025
28 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $209 · 2021: $323 · 2022: $379 · 2023: $718 · 2024: $999 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784 · Education: $60.46 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,784.23 |
| Education | $60.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.05 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $521.73 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $514.52 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $497.68 | 2019-2025 | Entyvio |
| Pfizer INC. | $295.62 | 2019-2025 | |
| Qol Medical, LLC | $267.38 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $233.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $127.98 | 2022-2024 | Zeposia |
| Ethicon US, LLC | $121.84 | 2021 | |
| Merck Sharp & Dohme LLC | $114.54 | 2019-2022 | |
| Braintree Laboratories, INC. | $102.15 | 2019-2023 | Sutab, Suflave |
| Laborie Medical Technologies Corp. | $90.45 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $80.06 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $78.12 | 2024-2025 | Ibsrela |
| Shionogi INC | $76.64 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $65.21 | 2023-2025 | |
| Boston Scientific Corporation | $39.04 | 2022-2023 | |
| Novo Nordisk INC | $35.64 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $34.63 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $32.79 | 2019-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $30.04 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $18.12 | 2024 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $15.78 | 2019 | |
| Alfasigma USA, INC. | $15.62 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.